


**Amendments to the Claims**

The listing of claims will replace all prior versions and listings of claims in the application.


**Listings of claims**

Claims 1 – 33 (cancelled)

34. (new) A compound having the formula **Ia** or **Ib**



**(Ia)**



**(Ib)**

wherein:

P represents a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one heteroatom is nitrogen;

$R^1$  is hydrogen;

$R^2$  is selected from:  $C_{1-6}$ alkyl, cyano, halogen,  $(CO)OR^{10}$ , and  $CONR^{10}R^{11}$ ;

$R^3$  is selected from:  $C_{1-6}$ alkyl, cyano, nitro,  $(CO)OR^4$ ,  $C_{1-6}alkylNR^4R^5$ ,  $OC_{2-6}alkylNR^4R^5$ ,  $CONR^4R^5$ ,  $SO_2R^4$ ,  $OSO_2R^4$  and  $(SO_2)NR^4R^5$ ;

$R^4$  is selected from: hydrogen,  $CF_3$  and  $C_{1-6}$ alkyl;

R<sup>5</sup> is selected from: hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylNR<sup>6</sup>R<sup>7</sup> and; wherein R<sup>4</sup> and R<sup>5</sup> may together form a 4-, 5-, 6- or 7-membered heterocyclic group containing one or more heteroatoms selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;

R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, (CO)C<sub>1-6</sub>alkyl, and wherein R<sup>6</sup> and R<sup>7</sup> may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;

R<sup>8</sup> and R<sup>9</sup> are independently selected from: hydrogen and C<sub>1-6</sub>alkyl and wherein R<sup>8</sup> and R<sup>9</sup> may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S;

R<sup>10</sup> is selected from hydrogen and C<sub>1-6</sub>alkyl;

R<sup>11</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylCN, C<sub>0-6</sub>alkylaryl, C<sub>2-6</sub>alkylOR<sup>8</sup>, C<sub>1-6</sub>alkyl(CO)NR<sup>6</sup>R<sup>7</sup>, C<sub>1-6</sub>alkyl(SO<sub>2</sub>)R<sup>6</sup>, C<sub>1-6</sub>alkyl(SO<sub>2</sub>)NR<sup>6</sup>R<sup>7</sup>, C<sub>0-6</sub>alkylheteroaryl, C<sub>0-6</sub>alkylC<sub>3-6</sub>heterocyclic group and C<sub>1-6</sub>alkylNR<sup>6</sup>R<sup>7</sup>; and wherein any C<sub>0-6</sub>alkylaryl and C<sub>0-6</sub>alkylheteroaryl may be substituted by one or more group Z; and wherein any C<sub>0-6</sub>alkylC<sub>3-6</sub>heterocyclic group may be substituted by one or more group Y;

Z is selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, OCF<sub>3</sub> and CF<sub>3</sub>;

Y is selected from: oxo, C<sub>2-6</sub>alkylOR<sup>8</sup>, C<sub>1-6</sub>alkyl, C<sub>0-6</sub>alkylaryl, C<sub>0-6</sub>alkylheteroaryl, OR<sup>8</sup> and C<sub>2-6</sub>alkylNR<sup>8</sup>R<sup>9</sup>;

m is 0, 1, 2, 3 or 4;

n is 0, 1, 2, 3 or 4;

as a free base or a salt, or a tautomer thereof.

35.(new) A compound according to claim 34, wherein;

P represents a 6-membered heteroaromatic ring containing one heteroatom selected independently from N and O;

R<sup>2</sup> is selected from: cyano, halogen, (CO)OR<sup>10</sup>, and CONR<sup>10</sup>R<sup>11</sup>;

R<sup>3</sup> is selected from: cyano, nitro, C<sub>1-6</sub>alkylNR<sup>4</sup>R<sup>5</sup>, OC<sub>2-6</sub>alkylNR<sup>4</sup>R<sup>5</sup>, CONR<sup>4</sup>R<sup>5</sup>, and (SO<sub>2</sub>)NR<sup>4</sup>R<sup>5</sup>;

R<sup>4</sup> is selected from: hydrogen and C<sub>1-6</sub>alkyl;

R<sup>5</sup> is selected from: C<sub>1-6</sub>alkyl and C<sub>1-6</sub>alkylNR<sup>6</sup>R<sup>7</sup> and; wherein R<sup>4</sup> and R<sup>5</sup> may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y;

R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, (CO)C<sub>1-6</sub>alkyl, and wherein R<sup>6</sup> and R<sup>7</sup> may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y;

R<sup>8</sup> and R<sup>9</sup> are independently selected from: hydrogen and C<sub>1-6</sub>alkyl and wherein R<sup>8</sup> and R<sup>9</sup> may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N and O;

R<sup>10</sup> is selected from hydrogen and C<sub>1-6</sub>alkyl;

R<sup>11</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylCN, C<sub>0-6</sub>alkylaryl, C<sub>2-6</sub>alkylOR<sup>8</sup>, C<sub>1-6</sub>alkyl(CO)NR<sup>6</sup>R<sup>7</sup>, C<sub>1-6</sub>alkyl(SO<sub>2</sub>)R<sup>6</sup>, C<sub>1-6</sub>alkyl(SO<sub>2</sub>)NR<sup>6</sup>R<sup>7</sup>, C<sub>0-6</sub>alkylheteroaryl, C<sub>0-6</sub>alkylC<sub>3-6</sub>heterocyclic group and C<sub>1-6</sub>alkylNR<sup>6</sup>R<sup>7</sup>; and wherein any C<sub>0-6</sub>alkylaryl may be substituted by one or more group Z;

Z is selected from halo, C<sub>1-6</sub>alkoxy, OCF<sub>3</sub> and CF<sub>3</sub>;

Y is selected from: oxo, C<sub>2-6</sub>alkylOR<sup>8</sup>, C<sub>1-6</sub>alkyl and C<sub>2-6</sub>alkylNR<sup>8</sup>R<sup>9</sup>;

m is 1 or 2;

n is 1.

36.(new) A compound according to claim 34, wherein P is pyridine.

37.(new) A compound according to claim 34, wherein R<sup>2</sup> is selected from cyano, (CO)OR<sup>10</sup>, and CONR<sup>10</sup>R<sup>11</sup>.

38.(new) A compound according to claim 34, wherein R<sup>2</sup> is CONR<sup>10</sup>R<sup>11</sup> and R<sup>11</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylCN, C<sub>2-6</sub>alkylOR<sup>8</sup>, C<sub>0-6</sub>alkylaryl, C<sub>0-6</sub>alkylheteroaryl; and wherein any C<sub>0-6</sub>alkylaryl and C<sub>0-6</sub>alkylheteroaryl may be substituted by one or more group Z and wherein Z is selected from C<sub>1-6</sub>alkoxy, OCF<sub>3</sub> and CF<sub>3</sub>.

39.(new) A compound according to claim 34, wherein R<sup>3</sup> is selected from: C<sub>1-6</sub>alkylNR<sup>4</sup>R<sup>5</sup>, OC<sub>2-6</sub>alkylNR<sup>4</sup>R<sup>5</sup>, CONR<sup>4</sup>R<sup>5</sup>, and (SO<sub>2</sub>)NR<sup>4</sup>R<sup>5</sup>; and wherein R<sup>4</sup> and R<sup>5</sup> may together form a 6-membered heterocyclic group containing one or two heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y, and wherein Y may be C<sub>1-6</sub>alkyl.

40.(new) A compound according to claim 34, wherein R<sup>3</sup> is selected from: C<sub>1-6</sub>alkylNR<sup>4</sup>R<sup>5</sup>, OC<sub>2-6</sub>alkylNR<sup>4</sup>R<sup>5</sup>, CONR<sup>4</sup>R<sup>5</sup>, and (SO<sub>2</sub>)NR<sup>4</sup>R<sup>5</sup>; and R<sup>5</sup> is C<sub>1-6</sub>alkylNR<sup>6</sup>R<sup>7</sup> and wherein R<sup>6</sup> and R<sup>7</sup> may together form a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y.

41.(new) A compound according to claim 34, wherein R<sup>3</sup> is C<sub>1-6</sub>alkylNR<sup>4</sup>R<sup>5</sup> and wherein R<sup>4</sup> and R<sup>5</sup> may together form a 6-membered heterocyclic group containing one or two heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y and wherein Y may be C<sub>1-6</sub>alkyl or oxo.

42.(new) A compound selected from:

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-morpholin-4-ylethyl)nicotinamide hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-methyl-*N*-(2-pyrrolidin-1-ylethyl)nicotinamide hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-(dimethylamino)ethyl)-*N*-methylnicotinamide hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide hydrochloride;

2-Hydroxy-3-[5-(piperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile hydrochloride;

3-[5-({4-[2-(Dipropylamino)ethyl]piperazin-1-yl}sulfonyl)pyridin-2-yl]-2-hydroxy-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-(5-{[4-(2-morpholin-4-ylethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-(5-{[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-(5-{[4-(2-methoxyethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-*N*-(3-methoxypropyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

*N*-[2-(Acetyl amino)ethyl]-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxybenzyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[4-(trifluoromethyl)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(trifluoromethyl)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(trifluoromethoxy)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[4-(trifluoromethoxy)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(tetrahydrofuran-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

*N*-Benzyl-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-propyl-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyphenyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(4-methoxyphenyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-3-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-4-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

*N*-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-[2-(methylsulfonyl)ethyl]-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

3-(5-Cyanopyridin-2-yl)-2-hydroxy-*N*-{2-[(4-methylpiperazin-1-yl)sulfonyl]ethyl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-sulfonamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-6-carboxamide hydrochloride;

3-[5-({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}sulfonyl)pyridin-2-yl]-2-hydroxy-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-(5-nitropyridin-2-yl)-1*H*-indole-5-carboxamide hydrochloride;

*N*-(2-Cyanoethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

*N*-Benzyl-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-propyl-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

*N*-[2-(Dimethylamino)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

3-(5-Cyanopyridin-2-yl)-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-methyl-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-methyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-isopropyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-(2-methoxyethyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(tetrahydrofuran-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(2-pyrrolidin-1-ylethyl)-1*H*-indole-5-carboxamide hydrochloride;

*N*-[3-(Dimethylamino)propyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-pyridin-3-yl-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(3-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-*N*-(tetrahydro-2*H*-pyran-4-yl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(4-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

*N*-(Cyanomethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

*N*-(2-Furylmethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-{5-[(3-oxopiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1*H*-indole-6-carbonitrile hydrochloride;  
3-{6-[2-(Diisopropylamino)ethoxy]pyrimidin-4-yl}-2-hydroxy-1*H*-indole-6-carbonitrile hydrochloride;  
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxylic acid hydrochloride;  
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]-1*H*-indole-5-carboxamide hydrochloride;  
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;  
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;  
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(2-thienyl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;  
*N*-[2-(Acetyl amino)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;  
*N*-(2-Cyanoethyl)-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;  
*N*-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;  
*N*-(Cyanomethyl)-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;  
2-Hydroxy-3-[5-(4-methylpiperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxylic acid carbamoylmethylamide hydrochloride;  
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(methylsulfonyl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;  
Methyl 3-fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-5-carboxylate hydrochloride;  
3-(5-Diethylaminomethyl-pyridin-2-yl)-2-hydroxy-1*H*-indole-5-carboxylic acid (2-methanesulfonyl-ethyl)-amide hydrochloride;

as a free base or another salt than hydrochloride, or a tautomer thereof;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

3-(4-Cyanopyridin-2-yl)-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide;  
2-Hydroxy-3-[5-(4-methylpiperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxylic acid  
(2-carbamoylethyl)amide;  
2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1*H*-indole-5-carboxylic acid  
methyl ester;  
2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1*H*-indole-5-carboxylic acid  
(thiophen-2-ylmethyl)-amide dihydrochloride;  
2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1*H*-indole-5-carboxylic acid  
benzylamide dihydrochloride;  
as a free base or a salt, or a tautomer thereof.

43.(new) A compound according to claim 42, which is in the form of a pharmaceutically acceptable salt.

44.(new) A compound selected from:

6-Chloronicotinic acid 1-oxide;  
Ethyl 6-chloronicotinate 1-oxide;  
1-[(6-Chloro-1-oxidopyridin-3-yl)carbonyl]-4-methylpiperazine;  
*tert*-Butyl 4-[(6-chloropyridin-3-yl)sulfonyl]piperazine-1-carboxylate ;  
(2-{4-[(6-Chloropyridin-3-yl)sulfonyl]piperazin-1-yl}ethyl)dipropylamine;  
4-(2-{4-[(6-Chloropyridin-3-yl)sulfonyl]piperazin-1-yl}ethyl)morpholine;  
1-[(6-Chloropyridin-3-yl)sulfonyl]-4-(2-pyrrolidin-1-ylethyl)piperazine;  
1-[(6-Chloropyridin-3-yl)sulfonyl]-4-(2-methoxyethyl)piperazine;  
6-Chloro-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;  
(2-{4-[(6-Chloropyridin-3-yl)sulfonyl]piperazin-1-yl}ethyl)dimethylamine;  
2-Oxo-*N*-(pyridin-2-ylmethyl)indoline-5-carboxamide;  
2-Oxo-*N*-(2-thienylmethyl)indoline-5-carboxamide;  
2-Oxo-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]indoline-5-carboxamide;  
*N*-[2-(Acetylamino)ethyl]-2-oxoindoline-5-carboxamide;  
*N*-(3-Methoxypropyl)-2-oxoindoline-5-carboxamide;  
6-Bromo-*N*-isopropyl-2-oxoindoline-5-carboxamide;  
6-Bromo-*N*-(2-methoxyethyl)-2-oxoindoline-5-carboxamide;  
6-Bromo-2-oxo-*N*-(tetrahydrofuran-2-ylmethyl)indoline-5-carboxamide;  
6-Bromo-2-oxo-*N*-(2-pyrrolidin-1-ylethyl)indoline-5-carboxamide;

*N*-[3-(Dimethylamino)propyl]-2-oxoindoline-5-carboxamide;  
*N*-(2-Methoxybenzyl)-2-oxoindoline-5-carboxamide;  
*N*-(3-Methoxybenzyl)-2-oxoindoline-5-carboxamide;  
*N*-(4-Methoxybenzyl)-2-oxoindoline-5-carboxamide;  
2-Oxo-*N*-(tetrahydro-2*H*-pyran-4-yl)indoline-5-carboxamide;  
*N*-Benzyl-2-oxoindoline-5-carboxamide;  
*N*-(2-Methoxyethyl)-2-oxoindoline-5-carboxamide;  
2-Oxo-*N*-propylindoline-5-carboxamide;  
*N*-[2-(Dimethylamino)ethyl]-2-oxoindoline-5-carboxamide;  
*N*-(2-Cyanoethyl)-2-oxoindoline-5-carboxamide;  
4-[(6-Chloro-1-oxidopyridin-3-yl)methyl]morpholine;  
4-[(6-Chloropyridin-3-yl)sulfonyl]morpholine;  
*N*-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-*N*-ethylethanamine;  
1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-methylpiperazine;  
1-[(6-chloro-1-oxidopyridine-3-yl)methyl]piperidine;  
4-[(6-Chloro-1-oxidopyridin-3-yl)methyl]piperazin-2-one;  
*N*-{2-[(4-Methylpiperazin-1-yl)sulfonyl]ethyl}-2-oxoindoline-5-carboxamide;  
4-{2-[(6-Chloropyrimidin-4-yl)oxy]ethyl}morpholine;  
*N*-{2-[(6-Chloropyrimidin-4-yl)oxy]ethyl}-*N*-isopropylpropan-2-amine;  
Ethyl 6-(6-cyano-2-hydroxy-1*H*-indol-3-yl)nicotinate;  
Methyl 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxylate;  
Methyl 3-{5-[(diethylamino)methyl]pyridin-2-yl}-2-hydroxy-1*H*-indole-5-carboxylate;  
Methyl 2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxylate;  
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxylic acid;  
Methyl 3-(4-cyanopyridin-2-yl)-2-hydroxy-1*H*-indole-5-carboxylate;  
as a free base or a salt, or a tautomer thereof.

45.(new) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound according to claim 34 in association with pharmaceutically acceptable carriers or diluents.

46.(new) The pharmaceutical formulation according to claim 45 for use in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

47.(new) A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **Ia** or **Ib** as defined in claim 34.

48.(new) A method of prevention and/or treatment of a human or animal suffering from dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica, by administering to such a mammal, a therapeutically effective amount of a compound of formula **Ia** or **Ib** as defined in claim 34.

49.(new) The method according to claim 48, wherein the prevention and/or treatment is for Alzheimer's Disease.


50.(new) A method of prevention and/or treatment of a human or animal suffering from amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, contraceptive medication, Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders, by administering to such a mammal, a therapeutically effective amount of a compound of formula **Ia** or **Ib** as defined in claim 34.

51.(new) A method of prevention and/or treatment of a human or animal suffering from predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and

androgenetic alopecia, by administering to such a mammal, a therapeutically effective amount of a compound of formula **Ia** or **Ib** as defined in claim 34.


52.(new) A method of prevention and/or treatment of a human or animal suffering from bone-related disorders, by administering to such a mammal, a therapeutically effective amount of a compound of formula **I** as defined in claim 34.

53.(new) A process for the preparation of a compound of formula **Ia** according to claim 34, wherein P, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>, m and n, unless otherwise specified, are defined in claim 34, comprising reacting a compound of formula **A**, wherein L<sup>1</sup> is a leaving group, with a compound of formula **D** to form a compound of formula **Ia**;




said reaction being carried out in an appropriate solvent at a temperature between +10 °C and +150 °C.

54.(new) A process for the preparation of a compound of formula **Ia** according to claim 34, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> and m, is as defined in claim 34, and halo is halogen, unless otherwise specified, comprising reacting a compound of formula **B** with a compound of formula **D** to form a compound of formula **Ia**;



said reaction being carried out in an appropriate solvent at a temperature between +10 °C and +150 °C.


55.(new) A process for the preparation of a compound of formula **Ia** according to claim 34, wherein R<sup>3</sup> is CONR<sup>4</sup>R<sup>5</sup>, comprising reacting a compound of formula **XIX**, wherein R<sup>4</sup> is C<sub>1-6</sub>alkyl, with the appropriate amine HNR<sup>4</sup>R<sup>5</sup>, to form a compound of formula **Ia**;



said reaction being carried out by;


- i) reacting the compound of formula **XIX** with the appropriate amine R<sup>4</sup>R<sup>5</sup>NH in a suitable solvent in the presence of a suitable reagent at a reaction temperature between 0 °C and reflux or;
- ii) reacting the compound of formula **XIX** with the appropriate amine R<sup>4</sup>R<sup>5</sup>NH neat or in a suitable solvent with or without a suitable base or an alkylamine base at a temperature between -20 °C and +150 °C.

56.(new) A process for the preparation of a compound of formula **Ia** according to claim 34, wherein  $R^2$  is  $\text{CONR}^{10}\text{R}^{11}$ , comprising amidation of a compound of formula **C**, wherein  $R^4$  is  $\text{C}_{1-6}$ alkyl, to form a compound of the formula **Ia**;



said reaction being carried out with the appropriate amine  $\text{HNR}^{10}\text{R}^{11}$  in a suitable solvent in the presence of trimethylaluminum and at a reaction temperature between  $-10\text{ }^{\circ}\text{C}$  and reflux.


57.(new) A process for the preparation of a compound of formula **Ia** according to claim 34, wherein  $R^2$  is  $\text{CONR}^{10}\text{R}^{11}$ , comprising amidation of a compound of formula **E**, to form a compound of the formula **Ia**, with the appropriate amine  $\text{HNR}^{10}\text{R}^{11}$ ;



carried out by activation of the acid function in a compound of formula **E** with;

- a) a halogenation reagent in a suitable solvent at a temperature between 0 °C and +80 °C, followed by the reaction with the appropriate amine  $\text{HNR}^{10}\text{R}^{11}$  in a suitable solvent with or without a suitable base at a temperature between -20 °C and +80 °C, or;
- b) a coupling reagent where the reaction is carried out in a suitable solvent at a temperature between +20 °C and +130 °C, followed by addition of the appropriate amine  $\text{HNR}^{10}\text{R}^{11}$ .

58.(new) A process for the preparation of a compound of formula **Ia** according to claim 34, wherein  $\text{R}^3$  is  $\text{C}_{1-6}\text{alkylNR}^4\text{R}^5$ , comprising fluorinating a compound of formula **XXIa** to form a compound of formula **Ib**.



said reaction being carried out in an appropriate solvent in the presence of a suitable fluorinating reagent and a suitable base at a reaction temperature between -40 °C and +80 °C.

59.(new) The use of the intermediates according to claim 44 for the preparation of a compound of formula **Ia** or **Ib** as defined in claim 34.